https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-18 / J. Immunol. 2014 Jul;193(2):735-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-18 / J. Immunol. 2014 Jul;193(2):735-452014-06-18 00:00:002019-02-15 09:21:24Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-11 / Front Oncol 2014;4:145
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-11 / Front Oncol 2014;4:1452014-06-11 00:00:002019-02-15 09:22:41Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-402014-06-09 00:00:002019-02-15 08:52:08Ovarian cancer biology and immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)2014-06-01 12:06:002019-07-17 12:06:29Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2005)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2005)2014-06-01 11:49:162019-07-17 11:49:36A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / Lancet Oncol. 2014 Jun;15(7):e257-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / Lancet Oncol. 2014 Jun;15(7):e257-672014-06-01 00:00:002019-02-15 08:35:59Clinical use of dendritic cells for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)2014-06-01 00:00:002014-06-01 00:00:00Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3085)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3085)2014-06-01 00:00:002021-08-09 07:54:01Intratumoral vaccination with activated allogeneic dendritic cells in patients with newly diganosed metastatic renal cell carcinoma (mRCC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3095)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3095)2014-06-01 00:00:002014-06-01 00:00:00Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/Pca.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3099)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3099)2014-06-01 00:00:002014-06-01 00:00:00Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa.
